Neuropathic Ocular Pain Therapeutics Market Size in the 7MM is projected to grow at a significant CAGR by 2036 | DelveInsight

DelveInsight's 'Neuropathic Ocular Pain Market Insights, Epidemiology and Market Forecast - 2036' report delivers an in-depth understanding of the Neuropathic Ocular Pain, historical and forecasted epidemiology, as well as the Neuropathic Ocular Pain market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Explore the intricate details of the Neuropathic Ocular Pain Treatment Market Report @ https://www.delveinsight.com/sample-request/neuropathic-ocular-pain-nop-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Key Takeaways from the Neuropathic Ocular Pain Market Report
• In March 2026, OKYO Pharma Limited reported positive Phase IIa exploratory results for urcosimod (0.05%) in NCP. The study showed clinically meaningful pain reduction, improved quality of life, and potential corneal nerve restoration signals versus placebo after 12 weeks of treatment. The findings will be presented at the 2026 ARVO Annual Meeting.
• In January 2026, OKYO Pharma announced FDA authorization of a compassionate-use IND application for urcosimod (0.05%) to treat a patient with severe NCP who had limited treatment options and no approved therapies available.
• NOP is increasingly recognized among patients with chronic ocular pain and dry eye like symptoms, with variations in disease burden, diagnosis, and clinical presentation across different patient populations and regions.
• In 2025, the United States accounted for the highest number of NOP cases among the 7MM, and this number is expected to increase throughout the study period.
• The observed female predominance and earlier onset of NOP highlight the importance of early diagnosis, gender-specific risk assessment, and targeted therapeutic strategies to improve disease management and patient outcomes.
• The leading Neuropathic Ocular Pain Companies include OKYO Pharma and others.
• Promising Neuropathic Ocular Pain Therapies include Urcosimod (0.05%; OK-101), and others.

Get a Free sample for the Neuropathic Ocular Pain Market Forecast, Size & Share Analysis Report @ https://www.delveinsight.com/sample-request/neuropathic-ocular-pain-nop-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Neuropathic Ocular Pain Overview
NOP is a chronic ocular pain condition caused by damage or dysfunction of the corneal nerves and somatosensory pathways, often occurring in the absence of significant visible ocular surface abnormalities. The condition is characterized by symptoms such as burning, stinging, dryness, photophobia, foreign body sensation, and severe eye discomfort, frequently associated with dry eye disease, refractive surgery, infections, trauma, autoimmune disorders, or systemic neuropathic conditions. NOP can significantly impair quality of life and is often difficult to diagnose and manage due to the overlap of symptoms with other ocular surface disorders and the complex underlying neuro-inflammatory mechanisms.

Neuropathic Ocular Pain Epidemiology Segmentation in the 7MM
• Total Cases of Several Eye Disorders and Surgeries
• Total Cases of Neuropathic Ocular Pain (NOP) in Several Eye Disorders and Surgeries
• Total Treated Cases of Neuropathic Ocular Pain (NOP)

Download the report to understand which factors are driving Neuropathic Ocular Pain Epidemiology trends @ https://www.delveinsight.com/sample-request/neuropathic-ocular-pain-nop-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Approved Therapies for Neuropathic Ocular Pain
NOP remains a significant unmet need due to the absence of approved disease-specific therapies and the limited effectiveness of current symptomatic treatments, creating substantial opportunities for novel therapeutic development and future research advancements.

Neuropathic Ocular Pain Pipeline Analysis
• Urcosimod (0.05%; OK-101): OKYO Pharma
Urcosimod (0.05%) is a lipid-conjugated chemerin peptide agonist targeting the ChemR23 receptor on ocular immune and nerve-related cells, developed for dry eye disease and neuropathic corneal pain. It has demonstrated anti-inflammatory and pain-reducing effects in preclinical models and showed significant efficacy in Phase II clinical trials for both neuropathic corneal pain and dry eye disease. The drug has received the first FDA IND and Fast Track designation for the treatment of Neuropathic Corneal Pain (NCP). As per company's 2026 corporate presentation, a Phase IIb/III multiple-dose study planned to initiate this year, with the topline results anticipated in H1 2027.

Discover more about therapies set to grab Major Neuropathic Ocular Pain Market Share @ https://www.delveinsight.com/sample-request/neuropathic-ocular-pain-nop-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Neuropathic Ocular Pain Companies
OKYO Pharma and others.

Neuropathic Ocular Pain Market Outlook
The NOP market is undergoing a gradual transformation, shifting from conventional symptomatic management toward targeted therapies addressing the underlying neuropathic and inflammatory mechanisms of ocular pain. Current treatment approaches primarily rely on artificial tears, topical corticosteroids, autologous serum tears, anti-inflammatory agents, systemic neuropathic pain medications, and supportive therapies, which often provide limited or temporary symptomatic relief without addressing the underlying corneal nerve dysfunction. Currently, there are no FDA approved therapies specifically for NOP, this creates substantial opportunities for emerging pipeline products and expedited regulatory pathways. Emerging therapies focused on reducing inflammation, modulating nerve signaling, and improving corneal nerve health are expected to reshape the treatment landscape and strengthen clinical and regulatory interest in novel ophthalmic pain therapies.

Neuropathic Ocular Pain Treatment Landscape
The uptake of therapies in NOP is expected to vary across conventional ocular surface treatments, systemic neuropathic pain therapies, and emerging targeted ophthalmic agents. Existing therapies such as lubricating eye drops, corticosteroids, cyclosporine formulations, and systemic neuromodulators currently account for the highest uptake despite their limited disease-specific efficacy. Among emerging therapies, urcosimod (0.05%; OK-101) is anticipated to witness relatively stronger future uptake owing to its anti-inflammatory and pain-reducing potential demonstrated in Phase II studies, while regenerative therapies such as autologous serum tears, platelet-rich plasma (PRP) eye drops, and nerve-regenerative approaches are expected to gain gradual adoption as clinical evidence and physician awareness continue to expand.

To know more about Neuropathic Ocular Pain Companies working in the treatment market, visit @ https://www.delveinsight.com/sample-request/neuropathic-ocular-pain-nop-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Scope of the Neuropathic Ocular Pain Market Report
• Coverage- 7MM
• Study Period- 2022-2036
• Forecast Period- 2026-2036
• Neuropathic Ocular Pain Companies- OKYO Pharma and others.
• Neuropathic Ocular Pain Therapies- Urcosimod (0.05%; OK-101), and others.
• Neuropathic Ocular Pain Therapeutic Assessment- Neuropathic Ocular Pain current marketed and emerging therapies
• Neuropathic Ocular Pain Market Dynamics: Neuropathic Ocular Pain market drivers and market barriers
• Neuropathic Ocular Pain Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Neuropathic Ocular Pain Unmet Needs, KOL's views, Analyst's views, Market Access and Reimbursement

Explore more information about the Neuropathic Ocular Pain Therapeutics Market Report @ https://www.delveinsight.com/sample-request/neuropathic-ocular-pain-nop-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary of Neuropathic Ocular Pain
4. Key Events of Neuropathic Ocular Pain
5. Epidemiology and Market Methodology of Neuropathic Ocular Pain
6. Neuropathic Ocular Pain Market Overview at a Glance
7. Disease Background And Overview of Neuropathic Ocular Pain
8. Epidemiology and Patient Population of Neuropathic Ocular Pain
9. Patient Journey of Neuropathic Ocular Pain
10. Marketed Therapies of Neuropathic Ocular Pain
11. Emerging Therapies of Neuropathic Ocular Pain
12. Neuropathic Ocular Pain: 7MM Analysis
13. Unmet Needs of Neuropathic Ocular Pain
14. SWOT Analysis of Neuropathic Ocular Pain
15. KOL Views of Neuropathic Ocular Pain
16. Market Access and Reimbursement of Neuropathic Ocular Pain
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.